Istituto Di Ricovero E Cura A Carattere Scientifico Centro Di Riferimento Oncologico Della Basilicata — Clinical Trial Site

19 Registered trials

4 Currently recruiting

Organisation

Istituto Di Ricovero E Cura A Carattere Scientifico Centro Di Riferimento Oncologico Della Basilicata

Location

Rionero In Vulture, Italy

Identifier

ORG-100048195

Address

Via Padre Pio 1, 85028, Italy

Departments

039026: Oncologia Medica
Department of Haematology
Dipartimento Onco-Ematologico
Ematologia
Ematologia e trapianto di cellule staminali
[email protected]
IT10029: Ematologia
IT10050: Ematologia
Medical oncology
N/A
Oncologia
U.O. Oncologia Medica
UO di ematologia e Trapianto Cellule Staminali
UO di ematologia e Trapianto Cellule Staminali - IRCCS-Centro di Riferimento Oncologico
UO di Oncologia Medica
UO Ematologia e Trapianto cellule staminali
UO Ematologia e Trapianto di Cellule Staminali
UO Oncologia Medica

Clinical trials at this site (19)

Search interface

Phase II trial of amivantamab plus monochemotherapy in platinum unfit NSCLC patients with EGFR exon20 insertion mutations Pending

2025-520676-26-00 Non-small cell lung cancer (NSCLC) 4
A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) s… Recruiting

2024-518223-29-00 Advanced or metastatic untreated EGFR mutation positive 4 2020-03-10
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
A clinical study of zilovertamab vedotin in people with large B-cell lymphoma (MK-2140-010) Recruiting

2024-515566-13-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2025-03-19
Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI… Recruiting

2024-517863-22-00 Study population consists in patients with a diagnosis 5 2024-12-01
A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB… Ended

2023-506139-13-00 Treatment naïve patients with MF 5 2024-01-04
A Phase 3 Study Comparing Pirtobrutinib (LOXO-305) to Bendamustine plus Rituximab in Untreated Patients with CLL/SLL Ended

2024-511599-33-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2021-12-22
Prephase treatment with prednisone +/- Vitamin D supplementation followed by immunochemotherapy in Elderly patients with Diffuse Large B-Cel… Ended

2024-511637-35-00 Elderly patients with Diffuse Large B-Cell Lymphoma (DL 5 2021-03-23
A clinical study to assess the effectiveness and safety of LOXO-305 compared to standard of care treatment chosen by the Investigator in pat… Ended

2023-507695-52-00 Mantle cell lymphoma 5 2021-03-05
A randomized trial that compares Carfilzomib - Lenalidomide - Dexamethasone (KRd) versus Lenalidomide - Dexamethasone (Rd) in new diagnosed … Ended

2024-513396-41-00 PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE > 5 2019-05-15
A Study of combination of Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) compared to VELCADE, Lenalidomide, and … Ended

2023-506125-10-00 Multiple Myeloma 5 2018-12-24
A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subject… Ended

2023-506112-40-00 R/R Multiple Myeloma 5 2018-09-26
Extended Access of Momelotinib for Subjects with Myelofibrosis Ended

2023-508018-41-00 Primary Myelofibrosis (PMF), Post-polycythemia Vera or 4 2018-07-27
Study to Evaluate Imetelstat (GRN163L) in Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Ended

2024-511348-25-00 Myelodysplastic syndromes (MDS) 10 2015-12-11
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S… Ended

2024-513559-34-00 Small Cell Lung Cancer (SCLC) 5 2022-07-19
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab (A-Brave) Ended

2024-514515-10-00 Breast Cancer 5 2016-06-16
Multicenter trial with carfilzomib combined with lenalidomide or cyclophopshamide with or without autologous transplant in newly diagnosed m… Ended

2024-516630-35-01 NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE 4 2015-01-12
THIS IS A CLINICAL STUDY WHICH EVALUATES TREATMENT WITH CHLORAMBUCIL AND RITUXIMAB FOLLOWED BY RITUXIMAB GIVEN UNDER THE SKIN IN PATIENTS W… Ended

2023-507291-52-00 Extranodal Marginal Zone Lymphoma 4 2014-03-24
Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma Ended

2023-506419-16-00 Advanced Classical Hodgkin Lymphoma 5 2013-01-08